Trials / Completed
CompletedNCT01110668
Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST)
Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST) Previously Treated With Imatinib
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess time-to-disease progression in patients with advanced gastrointestinal stromal tumor (GIST) previously treated with imatinib ≥600 mg.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nilotinib |
Timeline
- Start date
- 2008-09-01
- Primary completion
- 2011-09-01
- Completion
- 2011-09-01
- First posted
- 2010-04-27
- Last updated
- 2017-02-28
Locations
4 sites across 1 country: Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT01110668. Inclusion in this directory is not an endorsement.